Cargando…

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature

Glioblastoma is a devastating disease, for which biomarkers allowing a prediction of prognosis are urgently needed. microRNAs have been described as potentially valuable biomarkers in cancer. Here, we studied a panel of microRNAs in extracellular vesicles (EVs) from the serum of glioblastoma patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tzaridis, Theophilos, Reiners, Katrin S, Weller, Johannes, Bachurski, Daniel, Schäfer, Niklas, Schaub, Christina, Hallek, Michael, Scheffler, Björn, Glas, Martin, Herrlinger, Ulrich, Wild, Stefan, Coch, Christoph, Hartmann, Gunther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583802/ https://www.ncbi.nlm.nih.gov/pubmed/33003586 http://dx.doi.org/10.3390/ijms21197211

Ejemplares similares

Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications
por: Tzaridis, Theophilos, et al.
Publicado: (2021)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

Distress in Neuro-Oncology Patients and Its Implications for Communication
por: Roos, Carolin, et al.
Publicado: (2023)

Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma
por: Müller, Andreas, et al.
Publicado: (2016)

Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
por: Weller, Johannes, et al.
Publicado: (2022)

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
por: Schäfer, Niklas, et al.
Publicado: (2019)

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles
por: Brahmer, Alexandra, et al.
Publicado: (2023)

Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival
por: Schneider, Matthias, et al.
Publicado: (2020)

Postoperative Prolonged Mechanical Ventilation in Patients With Newly Diagnosed Glioblastoma—An Unrecognized Prognostic Factor
por: Schuss, Patrick, et al.
Publicado: (2020)

Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma
por: Schneider, Matthias, et al.
Publicado: (2021)

Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma — forfeiture of surgically achieved advantages?
por: Lehmann, Felix, et al.
Publicado: (2023)

Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity
por: Reiners, Katrin S., et al.
Publicado: (2014)

Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView
por: Bachurski, Daniel, et al.
Publicado: (2019)

RIG-I activation induces the release of extracellular vesicles with antitumor activity
por: Daßler-Plenker, Juliane, et al.
Publicado: (2016)

Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma
por: Schneider, Matthias, et al.
Publicado: (2021)

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
por: Kebir, Sied, et al.
Publicado: (2012)

News on the horizon in glioblastoma therapy
por: Herrlinger, Ulrich
Publicado: (2020)

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12
por: Giordano, Frank A., et al.
Publicado: (2019)

Reduction of microbleeds by immunosuppression in a patient with Aβ-related vascular inflammation
por: Traschütz, Andreas, et al.
Publicado: (2015)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma
por: Wach, Johannes, et al.
Publicado: (2021)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Glioblastoma and MiRNAs
por: Ahmed, Swalih P., et al.
Publicado: (2021)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates
por: Schneider, Matthias, et al.
Publicado: (2020)

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
por: Zeyen, Thomas, et al.
Publicado: (2022)

Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection
por: Borger, Valeri, et al.
Publicado: (2021)

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma
por: Kebir, Sied, et al.
Publicado: (2016)

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023)

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands
por: Serrano, Ruben, et al.
Publicado: (2021)

The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival
por: Schneider, Matthias, et al.
Publicado: (2021)

A-to-I editing in human miRNAs is enriched in seed sequence, influenced by sequence contexts and significantly hypoedited in glioblastoma multiforme
por: Paul, Deepanjan, et al.
Publicado: (2017)

Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies
por: Coenen, Martin, et al.
Publicado: (2015)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)

Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells
por: Li, Guanzhang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aotchsuvbfvtka9cstj8uo0r6r